OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study

• Xuan Wang,
• Jie Dai,
• Li Zhou,
• Robert Andtbacka,
• Jun Guo,
• Xue Bai,
• Lu Si,
• Bixia Tang,
• Chuanliang Cui,
• Qing Ji,
• Xinan Sheng,
• Siming Li,
• Zhihong Chi,
• Lili Mao,
• Bin Lian,
• Xieqiao Yan,
• Yan Kong,
• Jiayi Yu

Affiliations

Xuan Wang

Baylor Institute for Immunology Research, Dallas, Texas, USA

Jie Dai

Aff28 grid.418961.30000000404722713Regeneron Tarrytown NY USA

Li Zhou

Department of Acupuncture and Moxibustion, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei, China

Robert Andtbacka

Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA

Jun Guo

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Xue Bai

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Lu Si

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Bixia Tang

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Chuanliang Cui

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Qing Ji

Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Xinan Sheng

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Siming Li

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Zhihong Chi

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Lili Mao

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Bin Lian

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Xieqiao Yan

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Yan Kong

School of General Practice, Guangxi Medical University, Nanning, Guangxi, China

Jiayi Yu

NewLink Genetics Corp, Ames, Iowa, USA